seeding trials to promote a medical intervention were described as "trials of approved drugs [that] appear to serve little or no scientific purpose" and "thinly veiled attempts to entice doctors to prescribe a new drug being marketed by the company" in a special article in the "new england journal of medicine". the article, whose authors included u.s. food and drug administration commissioner david aaron kessler, also described a number of characteristics common to seeding trials: